These compounds have been developed to target specific vasopressin receptors (V1, V2, and V3) with varying affinities, allowing for more tailored therapeutic applications.

[1][2] The most prominent vasopressin analogues include desmopressin (dDAVP), terlipressin, and selepressin, each with distinct pharmacological profiles and clinical uses.

[3] Terlipressin, with higher V1 receptor selectivity, has found applications in managing variceal bleeding and hepatorenal syndrome.

Selepressin, a selective V1 receptor agonist, has been investigated for its potential in treating septic shock.

[1][2] Ongoing research continues to explore the therapeutic potential of vasopressin analogues in various clinical conditions, particularly in the management of shock states and fluid balance disorders.